Last reviewed · How we verify
Ovarian Function Suppression + Aromatase Inhibitor
This combination suppresses ovarian estrogen production while blocking the conversion of androgens to estrogen, reducing total circulating estrogen in premenopausal women with hormone receptor-positive breast cancer.
This combination suppresses ovarian estrogen production while blocking the conversion of androgens to estrogen, reducing total circulating estrogen in premenopausal women with hormone receptor-positive breast cancer. Used for Hormone receptor-positive, HER2-negative breast cancer in premenopausal women (adjuvant or metastatic setting).
At a glance
| Generic name | Ovarian Function Suppression + Aromatase Inhibitor |
|---|---|
| Sponsor | NRG Oncology |
| Drug class | Combination endocrine therapy (GnRH agonist/antagonist + aromatase inhibitor) |
| Target | GnRH receptor (ovarian suppression component) and aromatase enzyme (AI component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ovarian function suppression (OFS) agents such as GnRH agonists or antagonists shut down the ovaries' production of estrogen in premenopausal women. Aromatase inhibitors (AIs) block the enzyme aromatase, which converts androgens to estrogen in peripheral tissues. Together, this dual approach maximizes estrogen deprivation in hormone receptor-positive breast cancer by eliminating both ovarian and peripheral sources of estrogen.
Approved indications
- Hormone receptor-positive, HER2-negative breast cancer in premenopausal women (adjuvant or metastatic setting)
Common side effects
- Hot flashes
- Vaginal dryness
- Arthralgia/myalgia
- Fatigue
- Mood changes/depression
- Bone loss/osteoporosis
Key clinical trials
- Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (PHASE3)
- CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer (PHASE3)
- Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA) (PHASE3)
- Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer (PHASE2)
- OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk (PHASE4)
- ENDO-BRAIN: Effects of Endocrine Adjuvant Therapy with Aromatase Inhibitors on the Cognitive Function of Breast Cancer Patients
- Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) (PHASE3)
- CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: